实地研究和对因子IX变异FIX-R338L的相关研究在参与者治疗费达纳古elaparvovec治疗
Debra D Pittman1, Charles Carrieri2, Holly Soares2
1Rare Disease Research Unit, Pfizer Inc., Cambridge, Massachusetts, United States.
Thrombosis and haemostasis
|June 12, 2024
概括
在B型血友病基因治疗中测量因子IX-R338L活性的试验显示出变异性,特别是在低水平. 优化试验选择对于准确评估费达纳科根elaparvovec治疗疗效至关重要.
科学领域:
- 基因治疗是一种基因疗法.
- 血友病B研究研究
- 临床诊断 临床诊断 临床诊断
背景情况:
- 菲达诺基因elaparvovec,一种针对血友病B的新型基因疗法,利用一种腺相关病毒载体来表达一种高活性因子IX (FIX) 变体,FIX-R338L.
- 标准诊断试验,包括一阶段凝血 (OS) 和染色基质 (CS) 试验,用于量化FIX活性.
- 初步数据表明,在不同类型的测试中,FIX活动测量可能存在差异.
研究的目的:
- 通过使用常见的临床实验室测定来研究和理解FIX-R338L活性测量的变异性.
- 为了比较FIX-R338L活动测量在不同的OS和CS测试方法.
- 评估潜在干扰因素,如激活FIX (FIXa) 和外源FIX替代产品对测定结果的影响.
主要方法:
- 进行了一项国际性的多站点实地研究,其中包括一个中央实验室和18个当地实验室.
- 在所有参与站点使用标准化的协议,试剂和仪器仪表.
- 分析了费达诺基因elaparvovec临床试验1/2a阶段的参与者样本.
主要成果:
- FIX-R338L活性在基于的OS测定中比基于酸的OS和CS测定更高,与野生类型FIX对照不同.
- 在较低水平的FIX活性时,测试变异性更加明显.
- 在患者样本中没有检测到激活的FIX (FIXa),排除它是观察到的OS测定差异的原因. 发现外源FIX是添加剂,不会干扰内源FIX-R338L的测量.
结论:
- 在临床实验室使用OS和CS测定,可以可靠地测量FIX-R338L活性.
- 这项研究为测量内源性产生的FIX-R338L.L.时与不同试验相关的变异性提供了关键的见解.
- 研究结果可以为准确的FIX-R338L活性评估在接受基因治疗的血友病B患者的最佳实践的发展提供信息.
相关概念视频
Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


